Attention-Based Hierarchical Graph Autoencoder for Dose-Specific Single-Cell Resistance Dynamics

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: Understanding cellular adaptation to drug concentrations is critical for modeling therapeutic resistance. Current perturbation models treat doses as categorical variables and lack biological hierarchy, limiting their ability to model continuous dose-response trajectories and capture pathway-level regulatory rewiring. Results: We introduce a hierarchical graph attention autoencoder that models dose-specific single-cell transcriptional responses by integrating pathway, gene, and cell hierarchies with Long Short-Term Memory (LSTM)-based dose conditioning. Applied to GSE206125 (BRCA2-deficient ovarian cancer cells exposed to escalating olaparib concentrations T1–T320), our model reconstructs multiscale embeddings while predicting resistance phenotypes. Five-fold cross-validation with held-out doses demonstrates robust dose-level generalization (validation loss: 0.160 ± 0.045). The model extrapolates to unseen dose T320 with high fidelity (cosine similarity: 0.98) and successfully predicts trajectory responses at T640, beyond the training range. LSTM-based encoding captures non-linear transcriptional dynamics, including regime transitions between T40 and T80. Multi-head attention mechanisms consistently prioritize resistance-associated pathways (TP53-regulated transcription, oxidative stress signaling) and key regulatory genes (CDKN2A, YBX1). Ablation studies confirm that virtual nodes, attention mechanisms, and LSTM dose encoding each contribute uniquely to reconstruction fidelity and biological coherence. Conclusions: Our framework enables interpretable modeling of dose-dependent transcriptional trajectories with demonstrated extrapolation capability. While applied here to PARP inhibitor response in ovarian cancer, the architecture is designed to accommodate other dose-escalation studies as appropriately structured datasets become available.

Article activity feed